Background Syringoma has been known to recur following conventional treatments like cryotherapy and CO 2 laser. The risk of side effects, such as erythema, edema, scarring, and postinflammatory hyperpigmentation, results in unsatisfactory outcomes. Objective To evaluate the efficacy and safety of 1550‐nm nonablative fractional laser for treating syringoma. Methods We retrospectively analyzed the medical records of syringoma patients who underwent 1550‐nm fractional laser treatment. Two blinded dermatologists assessed the treatment efficacy of syringoma based on randomized clinical photographs before and after treatment, using the Periorbital Syringoma Severity Index (PSSI) score and a Global Improvement Scale. Additionally, the types and duration of any side effects occurring after the treatment were evaluated. Results A total of 8 patients underwent 22 sessions of 1550‐nm fractional laser treatment, averaging 2.75 sessions per patient (median, 2 sessions; range, 1–6 sessions). The female‐to‐male ratio was 7 : 1, with 3 patients (37.5%) having prior experience with CO 2 laser. The pretreatment PSSI score improved from 4.00 to 2.88 after treatment ( p = 0.03). Notably, 2 patients (25.0%) showed marked improvement, and 3 patients (37.5%) exhibited a moderate response. There was a strong correlation between the number of sessions and both the Global Improvement Scale ( r = 0.783, p = 0.02) and PSSI score reduction ( r = 0.619, p = 0.10). No scarring or dyspigmentation was observed postlaser treatment, and transient edema in 3 patients resolved on average after 13.7 days (median, 7 days). Conclusion Although this study is limited by its retrospective design and small sample size, its findings underscore the clinical efficacy of the 1550‐nm nonablative fractional laser for the treatment of syringoma. Considering its nonablative nature and short downtime, the 1550‐nm fractional laser is a safe and effective treatment alternative.